{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:46:11Z","timestamp":1793349971033,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With improved survival among people living with HIV (PLWH), non-AIDS-defining cancers have become increasingly prominent. Women living with HIV (WLWH) remain underrepresented in ovarian cancer trials, leaving limited evidence on the tolerability of standard therapies, including chemotherapy, anti-VEGF agents, and PARP inhibitors. These patients also face unique care barriers beyond biological uncertainties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective review included five WLWH diagnosed with ovarian cancer (June 2022\u2013March 2024). Three received anticancer treatment; one refused chemotherapy and was lost to follow-up; one had biopsy only. We collected data on demographics, HIV history, tumor characteristics, treatment exposure, adverse events (CTCAE v5.0), CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      counts, and HIV RNA, focusing safety and immune analyses on the three treated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median age was 51 years; four had stage III\u2013IV disease. No treatment-related deaths, persistent HIV rebound, or AIDS-defining events occurred. During first-line paclitaxel\/carboplatin, one patient developed grade 3 neutropenia managed with G-CSF, but later developed significant thrombocytopenia on niraparib requiring dose reduction and hospitalization. Among two patients receiving bevacizumab, CD4\n                      <jats:sup>+<\/jats:sup>\n                      patterns diverged: one showed a transient decline (387 to 259 cells\/\u03bcL) with concurrent nedaplatin; another maintained stable counts (150 to 200 cells\/\u03bcL). One patient had transient, self-limited HIV RNA elevation concurrent with disease progression, which resolved spontaneously.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This series provides real-world observations that platinum-based and targeted therapies may be delivered to selected WLWH with close monitoring. The heterogeneous CD4\n                      <jats:sup>+<\/jats:sup>\n                      responses highlight the need for individualized immune surveillance rather than attributing changes to any single agent. Integrated oncologic-HIV care and attention to socioeconomic barriers remain critical for this underrepresented population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1942370","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:29Z","timestamp":1790744189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world management of ovarian cancer in women living with HIV: treatment exposure, immune monitoring, and care barriers in a five-case series"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[{"name":"Shenzhen Third People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Shenzhen Third People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchuan","family":"Guo","sequence":"additional","affiliation":[{"name":"South China Hospital, Medical School, Shenzhen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Wan","sequence":"additional","affiliation":[{"name":"Shenzhen Third People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Liao","sequence":"additional","affiliation":[{"name":"Shenzhen Third People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Mao","sequence":"additional","affiliation":[{"name":"Shenzhen Third People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cui","sequence":"additional","affiliation":[{"name":"Shenzhen Third People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Cao","sequence":"additional","affiliation":[{"name":"Shenzhen University General Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Gao","sequence":"additional","affiliation":[{"name":"Shenzhen Third People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13627","article-title":"Sporotrichosis co\u2010infection with human immunodeficiency virus\/acquired immunodeficiency syndrome","volume":"66","author":"Uemura","year":"2023","journal-title":"Mycoses"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101701","article-title":"Johannesburg cancer study (Jcs): Contribution to knowledge and opportunities arising from 20 years of data collection in an African setting","volume":"65","author":"Chen","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104611","article-title":"Ovarian cancer\u2014epidemiology, classification, pathogenesis, treatment, and estrogen receptors\u2019 molecular backgrounds","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B4","first-page":"3849","article-title":"Non-Aids defining cancers: A comprehensive update on diagnosis and management","volume":"24","author":"Ceccarelli","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010070","article-title":"Changing prevalence of Aids and non-Aids-defining cancers in an incident cohort of people living with Hiv over 28 years","volume":"16","author":"Cattelan","year":"2023","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002533","article-title":"Gynecological radiotherapy in people living with human immunodeficiency virus: A semi-systematic literature review","volume":"32","author":"Fenlon","year":"2022","journal-title":"Int J Gynecological Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"62840","DOI":"10.12775\/QS.2025.44.62840","article-title":"Current insights into ovarian cancer: Epidemiology, diagnosis, and treatment","volume":"44","author":"Wo\u017aniak","year":"2025","journal-title":"Qual Sport"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061298","article-title":"Ovarian cancer treatments strategy: Focus on Parp inhibitors and immune check point inhibitors","volume":"13","author":"Nero","year":"2021","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/13543784.2021.1939305","article-title":"Advances in the treatment of platinum resistant epithelial ovarian cancer: An update on standard and experimental therapies","volume":"30","author":"Leung Soa","year":"2021","journal-title":"Expert Opin Invest Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01934-0","article-title":"Treatment of ovarian cancer beyond Parp inhibition: Current and future options","volume":"83","author":"Garg","year":"2023","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1131342","article-title":"Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511890","article-title":"An overview of Parp resistance in ovarian cancer from a molecular and clinical perspective","volume":"24","author":"Cordani","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-031-97242-3_10","article-title":"Role of immunotherapy in ovarian cancer: Advances, challenges, and future perspectives","volume-title":"Immunotherapies in Solid Tumors: A Team Medicine Approach","author":"Garg","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15111","article-title":"Multimodal treatment of primary advanced ovarian cancer","volume":"41","author":"Friedrich","year":"2021","journal-title":"Anticancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61122246","article-title":"Targeting ovarian neoplasms: Subtypes and therapeutic options","volume":"61","author":"Hong","year":"2025","journal-title":"Medicina"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1995.1105","article-title":"Effect of combination chemotherapy with cisplatin and cyclophosphamide on human immunodeficiency virus type-1 surrogate markers in a patient with advanced epithelial ovarian cancer","volume":"57","author":"Fishman","year":"1995","journal-title":"Gynecologic Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1022","article-title":"Advanced ovarian carcinoma managed in an Hiv-positive patient","volume":"48","author":"Rose","year":"1993","journal-title":"Gynecologic Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1224","article-title":"Advanced ovarian carcinoma diagnosed during pregnancy in a patient with human immunodeficiency virus infection","volume":"50","author":"Buckley","year":"1993","journal-title":"Gynecologic Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030378","article-title":"Deep thought on the Hiv cured cases: Where have we been and what lies ahead","volume":"15","author":"Xiao","year":"2025","journal-title":"Biomolecules"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2024.12.021","article-title":"Haematological toxicity of Parp inhibitors in advanced ovarian cancer: A systematic review and meta-analysis","volume":"305","author":"Maiorano","year":"2025","journal-title":"Eur J Obstetrics Gynecology Reprod Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.70251\/hyjr2348.35407422","article-title":"Parp inhibitors-associated adverse effects across multiple organ systems: A review of case reports from 2022 to 2025","author":"Vuong","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1473969","article-title":"Tertiary lymphoid structures: Exploring opportunities to improve immunotherapy in ovarian cancer","volume":"16","author":"Varghese","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41577-025-01149-2","article-title":"Regulatory T cell and endothelial cell crosstalk","volume":"25","author":"Piao","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: Opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41577-025-01211-z","article-title":"Linking tumour angiogenesis and tumour immunity","volume":"26","author":"Kabir","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47040273","article-title":"The hallmarks of ageing in human immunodeficiency virus infection and the impact of antiretroviral therapy on telomeres: A molecular perspective","volume":"47","author":"Apetroaei","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2196\/79219","article-title":"Machine learning in Hiv care and antiretroviral therapy: Systematic review","volume":"28","author":"Boudra","year":"2026","journal-title":"J Med Internet Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2024.100919","article-title":"Disease management teams in oncology: State of the art and the experience of a scientific institute of hospitalization and treatment (Irccs) in Rome, Italy","volume":"43","author":"Appetecchia","year":"2025","journal-title":"Brain Behavior Immunity-Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.12669\/pjms.41.6.10843","article-title":"Clinical effects of chemotherapy combined with bevacizumab and olaparib in treating advanced ovarian cancer and its effect on serum tumor markers and T-lymphocyte functions","volume":"41","author":"Liu","year":"2025","journal-title":"Pakistan J Med Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1576781","article-title":"Advances of Hdac inhibitors in tumor therapy: Potential applications through immune modulation","volume":"15","author":"Tian","year":"2025","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.33696\/aids.7.067","article-title":"Beyond viral suppression: Navigating structural barriers, aging and frailty, drug resistance, therapeutic innovations, and reproductive health challenges in the global Hiv\/Aids epidemic","volume":"7","author":"Eke","year":"2025","journal-title":"J AIDS HIV Treat"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/17455057251331714","article-title":"Qualitative analysis of patient and key informant interviews to inform integration of Hiv pre-exposure prophylaxis services into gynecology care in Alabama","volume":"21","author":"Pratt","year":"2025","journal-title":"Women's Health"},{"key":"B33","article-title":"The role of Cd4+ T memory subsets in Hiv infection: Immune response in people with Hiv and latency establishment","author":"Scaglioni","year":"2025"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132088","article-title":"Lymphoproliferations in people living with Hiv: Oncogenic pathways, diagnostic challenges, and new therapeutic opportunities","volume":"17","author":"Dolcetti","year":"2025","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1942370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:30Z","timestamp":1790744190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1942370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1942370"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1942370","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1942370"}}